Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
sEphB4-HSA + Pembrolizumab in EphrinB2-High Solid Tumors
NCT06493552Phase 3Recruiting
- Sponsor
- VasGene Therapeutics, Inc.
- Start
- Mar 2025
- Primary completion
- Sep 2029
- Modality
- Fc-Fusion Proteins
- Countries
- 1
01
Overview
A Phase 3 trial of sephb4-hsa in muscle-invasive bladder carcinoma (MIBC), metastatic urothelial carcinoma (mUC), sponsored by VasGene Therapeutics, Inc.. Started Mar 2025; status: recruiting.
02
Drugs
sephb4-hsa
03
Conditions
muscle-invasive bladder carcinoma (MIBC)metastatic urothelial carcinoma (mUC)
Beyond the preview
Go deeper on NCT06493552.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06493552.